DK0948522T3 - Terapeutiske og diagnostiske midler, der kan modulere cellulær fölsomhed over for cytokiner - Google Patents

Terapeutiske og diagnostiske midler, der kan modulere cellulær fölsomhed over for cytokiner

Info

Publication number
DK0948522T3
DK0948522T3 DK97909070T DK97909070T DK0948522T3 DK 0948522 T3 DK0948522 T3 DK 0948522T3 DK 97909070 T DK97909070 T DK 97909070T DK 97909070 T DK97909070 T DK 97909070T DK 0948522 T3 DK0948522 T3 DK 0948522T3
Authority
DK
Denmark
Prior art keywords
therapeutic
cytokines
diagnostic agents
signal transduction
present
Prior art date
Application number
DK97909070T
Other languages
English (en)
Inventor
Douglas J Hilton
Warren S Alexander
Donald Metcalf
Elizabeth M Viney
Tracy A Willson
Rachael T Richardson
Robyn Starr
Sandra E Nicholson
Nicos A Nicola
Original Assignee
Inst Medical W & E Hall
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPO3384A external-priority patent/AUPO338496A0/en
Priority claimed from AUPO5117A external-priority patent/AUPO511797A0/en
Application filed by Inst Medical W & E Hall filed Critical Inst Medical W & E Hall
Application granted granted Critical
Publication of DK0948522T3 publication Critical patent/DK0948522T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK97909070T 1996-11-01 1997-10-31 Terapeutiske og diagnostiske midler, der kan modulere cellulær fölsomhed over for cytokiner DK0948522T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPO3384A AUPO338496A0 (en) 1996-11-01 1996-11-01 Therapeutic and diagnostic agents
AUPO5117A AUPO511797A0 (en) 1997-02-14 1997-02-14 Therapeutic and diagnostic agents-II
PCT/AU1997/000729 WO1998020023A1 (en) 1996-11-01 1997-10-31 Therapeutic and diagnostic agents capable of modulating cellular responsiveness to cytokines

Publications (1)

Publication Number Publication Date
DK0948522T3 true DK0948522T3 (da) 2008-09-22

Family

ID=25645307

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97909070T DK0948522T3 (da) 1996-11-01 1997-10-31 Terapeutiske og diagnostiske midler, der kan modulere cellulær fölsomhed over for cytokiner

Country Status (13)

Country Link
US (1) US20080166730A1 (da)
EP (2) EP1975234A2 (da)
JP (2) JP2001502183A (da)
KR (2) KR100719080B1 (da)
CN (2) CN1253565A (da)
AT (1) ATE398136T1 (da)
CA (1) CA2270171A1 (da)
DE (1) DE69738767D1 (da)
DK (1) DK0948522T3 (da)
ES (1) ES2308785T3 (da)
GB (1) GB2331753A (da)
NO (1) NO992116L (da)
WO (1) WO1998020023A1 (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495518B1 (en) 1994-06-13 2002-12-17 Vanderbilt University Method for importing biologically active molecules into cells
CA2230986A1 (en) * 1997-05-07 1998-11-07 Smithkline Beecham Corporation Epo primary response gene 1, eprg1
AU8484698A (en) * 1997-07-18 1999-02-10 Schering Corporation Suppressors of cytokine signaling socs16; related reagents
AU1205599A (en) * 1997-11-03 1999-05-24 Incyte Pharmaceuticals, Inc. Suppressor of cytokine signaling
EP1053007A2 (en) * 1998-02-11 2000-11-22 Beth Israel Deaconess Medical Center Methods and compositions for modulating leptin activity
JP2002507418A (ja) * 1998-03-23 2002-03-12 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー サイトカインシグナル伝達のサプレッサー
EP0953636A3 (en) 1998-03-23 2000-03-29 Smithkline Beecham Plc Cytokine signal regulators
US6620382B1 (en) * 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
CA2329053A1 (en) * 1998-05-28 1999-12-02 Incyte Pharmaceuticals, Inc. Human socs proteins
SE9803398D0 (sv) * 1998-10-06 1998-10-06 Sahltech Ab "New use"
US7078174B1 (en) 1998-12-21 2006-07-18 The Walter & Eliza Hall Institute Of Medical Research Screening methods using SOCS box-containing peptides
AU4651900A (en) * 1999-04-20 2000-11-02 Beth Israel Deaconess Medical Center Methods and compositions for modulating ciliary neurotrophic factor activity
US6541244B1 (en) * 1999-06-07 2003-04-01 Cedars-Sinai Medical Center Suppressor of cytokine signaling (SOCS)-3 promoter and methods for its use in genetic therapy in humans
AU784277B2 (en) * 1999-11-16 2006-03-02 Walter And Eliza Hall Institute Of Medical Research, The An animal model for studying hormone signalling and method of modulating the signalling
ATE395926T1 (de) * 1999-11-16 2008-06-15 Inst Medical W & E Hall Tiermodell für hormonsignalstudien und verfahren zum verändern der signalübertragung
WO2001079555A2 (en) * 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
CA2425194A1 (en) * 2000-10-09 2002-04-18 Andrew Nash Modulating cytokine or hormone signalling in an animal comprising up-regulating the expression of socs sequence in the animal
GB2373502A (en) * 2000-11-08 2002-09-25 Smithkline Beecham Corp Suppressor of cytokine signalling 4 (SOCS4)
EP1341913A2 (en) * 2000-12-14 2003-09-10 PHARMACIA & UPJOHN COMPANY Socs (suppressor of cytokine signaling)
AUPR556601A0 (en) * 2001-06-08 2001-07-12 Ludwig Institute For Cancer Research Therapeutic and diagnostic molecules - II
WO2003072778A1 (en) * 2002-02-27 2003-09-04 Genox Research, Inc. Method of examining allergic disease
WO2005086800A2 (en) 2004-03-04 2005-09-22 Vanderbilt University Cell-penetrating socs polypeptides that inhibit cytokine-induced signaling
JP2005312364A (ja) * 2004-04-28 2005-11-10 Mitsuo Itakura 糖尿病治療剤スクリーニング方法
WO2006088010A1 (ja) * 2005-02-15 2006-08-24 Toagosei Co., Ltd. 抗菌ペプチド及びその利用
US20120308570A1 (en) * 2009-05-08 2012-12-06 Tatiana Kolesnik Methods for treating diseases
KR101124622B1 (ko) * 2009-10-26 2012-03-19 한국생명공학연구원 Ｓｏｃｓ２ 유전자의 발현을 조절하여 자연 살해 세포를 활성화시키는 방법
JP2019505498A (ja) * 2015-12-16 2019-02-28 ザ・ウォルター・アンド・エリザ・ホール・インスティテュート・オブ・メディカル・リサーチ Ｎｋ細胞におけるサイトカイン誘導性ｓｈ２タンパク質の阻害

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4420782C1 (de) * 1994-06-15 1995-08-17 Fluegge Ulf Ingo Prof Dr DNA-Sequenz, kodierend einen 2-Oxoglutarat/Malat-Translokator, Plasmide, Bakterien, Hefen und Pflanzen enthaltend diesen Transporter
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
JPH07291996A (ja) * 1994-03-01 1995-11-07 Yuu Honshiyo ヒトにおけるプログラムされた細胞死に関連したポリペプチド、それをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞、そのポリペプチドの抗体、およびそのポリペプチドまたはその抗体を含有する薬学的組成物
WO1996039427A1 (en) * 1995-06-05 1996-12-12 Trustees Of Dartmouth College Ligand-stimulated gene expression
DE69735820T2 (de) * 1997-01-10 2006-12-21 Kishimoto, Tadamitsu, Tondabayashi Neues protein, welches die funktion von stat reguliert
AU8484698A (en) * 1997-07-18 1999-02-10 Schering Corporation Suppressors of cytokine signaling socs16; related reagents

Also Published As

Publication number Publication date
CA2270171A1 (en) 1998-05-14
CN101280305A (zh) 2008-10-08
GB9905020D0 (en) 1999-04-28
JP2001502183A (ja) 2001-02-20
WO1998020023A1 (en) 1998-05-14
JP2009060903A (ja) 2009-03-26
GB2331753A (en) 1999-06-02
ES2308785T3 (es) 2008-12-01
EP1975234A2 (en) 2008-10-01
DE69738767D1 (de) 2008-07-24
NO992116D0 (no) 1999-04-30
ATE398136T1 (de) 2008-07-15
EP0948522A1 (en) 1999-10-13
KR100719080B1 (ko) 2007-05-16
EP0948522B1 (en) 2008-06-11
EP0948522A4 (en) 2001-09-19
US20080166730A1 (en) 2008-07-10
NO992116L (no) 1999-06-29
CN1253565A (zh) 2000-05-17
KR20060053007A (ko) 2006-05-19
KR20000053017A (ko) 2000-08-25

Similar Documents

Publication Publication Date Title
DK0948522T3 (da) Terapeutiske og diagnostiske midler, der kan modulere cellulær fölsomhed over for cytokiner
ATE217754T1 (de) Verwendung von aerogelen in der landwirtschaft
ATE413386T1 (de) Ppar-gamma modulatoren
DE69431056D1 (de) Substituierte oxazolyl-derivate zur behandlung von entzündungen
EP0873363A4 (en) NEW HIGH-AFFINE HUMAN ANTIBODIES AGAINST TUMORANTIGENS
DK0804163T3 (da) Forbedret fremgangsmåde til stabilisering af biologiske stoffer under tørring og efterfølgende opbevaring samt præparater deraf
GEP20043349B (en) Methods of Controlling Cutworm Pests
DE69832293D1 (de) Zubereitungen zur abgabe von negativ geladenen molekülen
DE69821667D1 (de) Kardioverter zur Behandlung von Vorhofflattern
ATE286125T1 (de) Regulation der genexpression von bcl-2
FI830708L (fi) 1,2,4-triazin- och pyrazinderivat
ATE79270T1 (de) Verwendung von interzellularen adhaesionsmolek¨len und deren bindungsliganden bei der behandlung von asthma.
MY107573A (en) 2,4- and 2, 5-substituted pyridine-n-oxides, processes for their preparation and their use.
DE3482647D1 (de) Vorrichtung zur digital-kontrollierten eichung des frequenzverhaltens von verstaerkern.
DE69924738D1 (de) Modulierung von mlk- (multiple lineage kinase) proteinen
TR28583A (tr) Arilpirrol insektisidal ve akarisidal unsurlarin suspansiyon konsantrat terkipleri.
DK0638068T3 (da) Fremgangsmåde til fremstilling af (S)-3-amino-1-substitueret-pyrrolidiner
DE69906568D1 (de) Behandlung von hämorrhagischem virusfieber mit protein c
DE69827387D1 (de) Verwendung von pramipexol zur behandlung von restless-legs-syndrom
DE60017924D1 (de) Rekombinante, adenovirale vektoren und ihre verwendung zur behandlung von leberzirrhose
ATE226591T1 (de) Oligopeptide hergeleitet von fragmenten des c- reaktiven proteins
DE3787954D1 (de) Verwendung von 5-(Subst. Phenyl)- Oxazolidinonderivaten zur Behandlung von Depressionen.
NO993180D0 (no) N-(pyridinylamino)isoindoler og beslektede forbindelser
ATE165594T1 (de) Triarylethylenderivate zur therapeutischen verwendung
ES2061775T3 (es) Derivados de estrobirulina, su obtencion y empleo.